Beta-blocker therapy and symptoms of depression,fatigue, and sexual dysfunction |
| |
| Authors: | Ko Dennis T Hebert Patricia R Coffey Christopher S Sedrakyan Artyom Curtis Jeptha P Krumholz Harlan M |
| |
| Affiliation: | Section of CardiovascularMedicine, Department of Medicine (Drs Ko, Hebert, Curtis, and Krumholz), andSection of Health Policy and Administration, Department of Epidemiology andPublic Health (Drs Sedrakyan and Krumholz), Yale University School of Medicine,and Yale–New Haven Hospital Center for Outcomes Research and Evaluation(Dr Krumholz), New Haven, Conn; and Department of Biostatistics, Universityof Alabama at Birmingham (Dr Coffey). |
| |
| Abstract: | Context  -Blocker therapy remains substantially underused in cardiac patientsdespite its proven mortality benefits. Reluctance to prescribe these agentsmay derive from concerns about their association with symptoms of depression,fatigue, and sexual dysfunction. Objective To determine the association of -blockers with depressive symptoms,fatigue, and sexual dysfunction by performing a quantitative review of randomizedtrials that tested -blockers in myocardial infarction, heart failure,and hypertension. Data Sources Randomized trials of -blockers used in the treatment of myocardialinfarction, heart failure, or hypertension were identified by searching theMEDLINE database for English-language articles (1966-2001). In addition, wesearched the reference lists of previously published trials and reviews of -blockersfor additional studies. Study Selection Criteria for inclusion of trials in the review were: random allocationof study treatments, placebo control, noncrossover design, enrollment of atleast 100 patients, and a minimum of 6 months of follow-up. The initial searchproduced 475 articles, 42 of which met these criteria. Fifteen of these trialsreported on depressive symptoms, fatigue, or sexual dysfunction and were selectedfor inclusion. Data Extraction For each trial, 1 author abstracted the frequency of adverse eventsin the -blocker and placebo groups and the numbers of patients randomizedto the treatment groups. Two other authors verified the counts of events,and all authors adjudicated any discrepancies. Two different types of informationon adverse events were abstracted: patient-reported symptoms and withdrawalof therapy due to a specified symptom. We categorized the tested -blockersby generation (early vs late) and lipid solubility (high vs low to moderate). Data Synthesis The 15 trials involved more than 35 000 subjects. -Blockertherapy was not associated with a significant absolute annual increase inrisk of reported depressive symptoms (6 per 1000 patients; 95% confidenceinterval [CI], 7 to 19). -Blockers were associated with a smallsignificant annual increase in risk of reported fatigue (18 per 1000 patients;95% CI, 5-30), equivalent to 1 additional report of fatigue for every 57 patientstreated per year with -blockers. -Blockers were also associatedwith a small, significant annual increase in risk of reported sexual dysfunction(5 per 1000 patients; 95% CI, 2-8), equivalent to one additional report forevery 199 patients treated per year. None of the risks of adverse effectsdiffered significantly by degree of -blocker lipid solubility. The riskassociated with reported fatigue was significantly higher for early-generationthan for late-generation -blockers (P = .04). Conclusion The conventional wisdom that -blocker therapy is associated withsubstantial risks of depressive symptoms, fatigue, and sexual dysfunctionis not supported by data from clinical trials. There is no significant increasedrisk of depressive symptoms and only small increased risks of fatigue andsexual dysfunction. The risks of these adverse effects should be put in thecontext of the documented benefits of these medications. |
| |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ |
| 点击此处可从《》浏览原始摘要信息 |
|
点击此处可从《》下载全文 |
|
